Alirocumab significantly lowers LDL-C levels by inhibiting PCSK9. In the ODYSSEY OUTCOMES trial, patients achieved an average LDL-C reduction of 48.5%, with some reaching LDL-C levels <25 mg/Dl. In the PACMAN-AMI trial, after 52 weeks of alirocumab combined with statin therapy, PAV in non-infarct-related arteries significantly decreased and MLA increased. The ARCHITECT trial demonstrated that 78 weeks of alirocumab treatment promoted coronary plaque regression and stabilization, particularly in patients with FH. It was approved by FDA in 2015. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.